Grufity logo
Grufity logo

Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio

$139Million | No. of Holdings #35

SUPERSTRING CAPITAL MANAGEMENT LP Performance

2026 Q1-0.97%
YTD-0.97%
2025+60.47%

About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings

On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $140 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are SMMT, IMVT, COGT. The fund has invested 12.1% of it's portfolio in SUMMIT THERAPEUTICS INC and 6.3% of portfolio in IMMUNOVANT INC . <br><br> The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), TERNS PHARMACEUTICALS INC (TERN) and DYNAVAX TECHNOLOGIES CORP (DVAX) stocks. They significantly reduced their stock positions in CENTURY THERAPEUTICS INC (IPSC), TAYSHA GENE THERAPIES INC (TSHA) and BRIGHT MINDS BIOSCIENCES INC (DRUG). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in SUMMIT THERAPEUTICS INC (SMMT), DEFINIUM THERAPEUTICS INC and VIR BIOTECHNOLOGY INC (VIR). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), TRAVERE THERAPEUTICS INC (TVTX) and CELLDEX THERAPEUTICS INC NEW (CLDX).
SUPERSTRING CAPITAL MANAGEMENT LP Equity Portfolio Value
Last Reported on: 14 May, 2026
$139Million
  as of May 14, 2026

SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500

Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of -0.97% in the last quarter. In trailing 12 months, it's portfolio return was 69.04%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
summit therapeutics inc 16,928,900
definium therapeutics inc 6,642,610
vir biotechnology inc 6,545,710
vaxcyte inc 6,418,480
vertex pharmaceuticals inc 4,916,400
iqvia hldgs inc 4,377,420
maplight therapeutics inc 3,906,190
arvinas inc 3,313,770
New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP

Additions

Ticker% Inc.
genmab a/s 574
travere therapeutics inc 170
celldex therapeutics inc new103
trevi therapeutics inc 69.64
savara inc 59.34
zai lab ltd 40.11
immunovant inc 23.88
palatin technologies inc 5.88
Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP

Reductions

Ticker% Reduced
century therapeutics inc -74.23
taysha gene therapies inc -73.67
bright minds biosciences inc-71.85
axsome therapeutics inc. -70.03
protara therapeutics inc -66.26
oric pharmaceuticals inc -54.88
cabaletta bio inc -52.69
urogen pharma ltd -46.08
SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock

Sold off

Ticker$ Sold
dynavax technologies corp -8,083,600
rezolute inc -1,212,480
terns pharmaceuticals inc -17,928,600
mind medicine mindmed inc -5,693,460
ocular therapeutix inc -5,075,490
palisade bio inc -862,692
amicus therapeutics inc -5,025,240
avalo therapeutics inc -2,784,160
SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks

Sector Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 79.7% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare79.7
Others20.3

Market Cap. Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 26.1% of it's portfolio invested in the large-cap and mega-cap stocks.

  • SMALL-CAP
  • LARGE-CAP
  • MID-CAP
  • UNALLOCATED
  • MICRO-CAP
Category%
SMALL-CAP27.9
LARGE-CAP26.1
MID-CAP20.7
UNALLOCATED20.3
MICRO-CAP4.6

Stocks belong to which Index?

About 70.4% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200062.3
Others29.5
S&P 5008.1
Top 5 Winners (%)%
IPSC
century therapeutics inc
80.0 %
ORIC
oric pharmaceuticals inc
39.8 %
BMEA
biomea fusion inc
23.4 %
CABA
cabaletta bio inc
16.8 %
UTHR
united therapeutics corp del
16.8 %
Top 5 Winners ($)$
COGT
cogent biosciences inc
0.9 M
ORIC
oric pharmaceuticals inc
0.8 M
CABA
cabaletta bio inc
0.8 M
UTHR
united therapeutics corp del
0.8 M
CLDX
celldex therapeutics inc new
0.6 M
Top 5 Losers (%)%
URGN
urogen pharma ltd
-17.9 %
TVTX
travere therapeutics inc
-16.4 %
TSHA
taysha gene therapies inc
-11.8 %
SVRA
savara inc
-7.8 %
GMAB
genmab a/s
-7.8 %
Top 5 Losers ($)$
URGN
urogen pharma ltd
-3.0 M
SVRA
savara inc
-0.7 M
TSHA
taysha gene therapies inc
-0.6 M
TVTX
travere therapeutics inc
-0.6 M
GMAB
genmab a/s
-0.4 M

SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP

SUPERSTRING CAPITAL MANAGEMENT LP has 35 stocks in it's portfolio. About 57.9% of the portfolio is in top 10 stocks. URGN proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.

$139.97MTotal Value
60.00Positions
14 May, 2026Last Reported
Current holdings of Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP, last reported on 14 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Belite Bio Inc over time
0%0.00
$0.00
0%
decreased 100 percentsold off
DRUG
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc

DRUG
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Bright Minds Biosciences Inc over time
0.69%13,311
$971.3K
0.69%
decreased 71.85 percentreduced
ENTX
Entera Bio Ltd

Entera Bio Ltd

ENTX
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Entera Bio Ltd over time
0%0.00
$0.00
0%
decreased 100 percentsold off
GMAB
Genmab A/S

Genmab A/S

GMAB
SUPERSTRING CAPITAL MANAGEMENT LP's holding in Genmab A/S over time
3.77%196,709
$5.28M
3.77%
increased 574.54 percentadded